The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

Area of Science:

• Oncology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a critical pathway in cancer.
• Rapamycin and its analogs are established mTOR inhibitors with known toxicities, primarily documented in transplant patients.
• Emerging mTOR inhibitors share similar pharmacokinetic and toxicity profiles with rapamycin.

Purpose of the Study:

• To review the toxicity profiles of mTOR inhibitors used in cancer therapy.
• To discuss the clinical management of common mTOR inhibitor-associated toxicities.

Main Methods:

• Literature review of clinical trials and case reports on mTOR inhibitor toxicities.
• Analysis of reported adverse events, focusing on severity and management strategies.

Main Results:

• The most frequent toxicities associated with mTOR inhibitors include mucositis and pneumonitis.
• These toxicities are generally mild to moderate and manageable through dose adjustments and supportive care.
• Treatment discontinuation due to toxicities is rare.

Conclusions:

• mTOR inhibitors represent a significant therapeutic class in oncology.
• Understanding and managing their distinct toxicity profiles, particularly mucositis and pneumonitis, is crucial for effective clinical application.
• While pneumonitis pathogenesis remains under investigation, current management strategies are effective in preventing treatment cessation.